PURPOSE: The purpose of this prospective study was to investigate the proton-beam-induced changes in apparent diffusion coefficient (ADC) values of ocular melanoma treated with proton-beam therapy (PBT) in patients undergoing long-term magnetic resonance imaging (MRI) follow-up and to assess whether variations in ADC constitute a reliable biomarker for predicting and detecting the response of ocular melanoma to PBT. METHODS: Seventeen patients with ocular melanoma treated with PBT were enrolled. All patients underwent conventional MRI and diffusion-weighted imaging (DWI) at baseline and 1, 3, 6, and 18 months after the beginning of therapy. Tumor volumes and ADC values of ocular lesions were measured at each examination. Tumor volumes and mean ADC measurements of the five examination series were compared; correlation of ADC values and tumor regression was estimated. RESULTS: Mean ADC values of ocular melanomas significantly increased already 1 month after therapy whereas tumor volume significantly decreased only 6 months after therapy. Pretreatment ADC value of ocular melanomas and early change in ADC value 1 month after therapy significantly correlated with tumor regression. CONCLUSIONS: In ocular melanoma treated with PBT, ADC variations precede volume changes. Both pretreatment ADC and early change in ADC value may predict treatment response, thus expanding the role of DWI from diagnostic to prognostic.
PURPOSE: The purpose of this prospective study was to investigate the proton-beam-induced changes in apparent diffusion coefficient (ADC) values of ocular melanoma treated with proton-beam therapy (PBT) in patients undergoing long-term magnetic resonance imaging (MRI) follow-up and to assess whether variations in ADC constitute a reliable biomarker for predicting and detecting the response of ocular melanoma to PBT. METHODS: Seventeen patients with ocular melanoma treated with PBT were enrolled. All patients underwent conventional MRI and diffusion-weighted imaging (DWI) at baseline and 1, 3, 6, and 18 months after the beginning of therapy. Tumor volumes and ADC values of ocular lesions were measured at each examination. Tumor volumes and mean ADC measurements of the five examination series were compared; correlation of ADC values and tumor regression was estimated. RESULTS: Mean ADC values of ocular melanomas significantly increased already 1 month after therapy whereas tumor volume significantly decreased only 6 months after therapy. Pretreatment ADC value of ocular melanomas and early change in ADC value 1 month after therapy significantly correlated with tumor regression. CONCLUSIONS: In ocular melanoma treated with PBT, ADC variations precede volume changes. Both pretreatment ADC and early change in ADC value may predict treatment response, thus expanding the role of DWI from diagnostic to prognostic.
Authors: T Sugahara; Y Korogi; M Kochi; I Ikushima; Y Shigematu; T Hirai; T Okuda; L Liang; Y Ge; Y Komohara; Y Ushio; M Takahashi Journal: J Magn Reson Imaging Date: 1999-01 Impact factor: 4.813
Authors: Colleen C McLaughlin; Xiao-Cheng Wu; Ahmedin Jemal; Howard J Martin; Lisa M Roche; Vivien W Chen Journal: Cancer Date: 2005-03-01 Impact factor: 6.860
Authors: P de Graaf; P J W Pouwels; F Rodjan; A C Moll; S M Imhof; D L Knol; E Sanchez; P van der Valk; J A Castelijns Journal: AJNR Am J Neuroradiol Date: 2011-10-27 Impact factor: 3.825
Authors: Pietro Valerio Foti; Renato Farina; Maria Coronella; Stefano Palmucci; Angelo Montana; Alessandra Sigona; Michele Reibaldi; Antonio Longo; Andrea Russo; Teresio Avitabile; Rosario Caltabiano; Lidia Puzzo; Marco Ragusa; Cesare Mariotti; Pietro Milone; Giovanni Carlo Ettorre Journal: Radiol Med Date: 2015-01-13 Impact factor: 3.469
Authors: Sungheon Kim; Laurie Loevner; Harry Quon; Eric Sherman; Gregory Weinstein; Alex Kilger; Harish Poptani Journal: Clin Cancer Res Date: 2009-02-01 Impact factor: 12.531
Authors: Małgorzata Solnik; Natalia Paduszyńska; Anna M Czarnecka; Kamil J Synoradzki; Yacoub A Yousef; Tomasz Chorągiewicz; Robert Rejdak; Mario Damiano Toro; Sandrine Zweifel; Katarzyna Dyndor; Michał Fiedorowicz Journal: Cancers (Basel) Date: 2022-06-27 Impact factor: 6.575
Authors: Daniël P de Bruyn; Aaron B Beasley; Robert M Verdijk; Natasha M van Poppelen; Dion Paridaens; Ronald O B de Keizer; Nicole C Naus; Elin S Gray; Annelies de Klein; Erwin Brosens; Emine Kiliç Journal: Biomedicines Date: 2022-02-21
Authors: Pietro Valerio Foti; Mario Travali; Renato Farina; Stefano Palmucci; Corrado Spatola; Luigi Raffaele; Vincenzo Salamone; Rosario Caltabiano; Giuseppe Broggi; Lidia Puzzo; Andrea Russo; Michele Reibaldi; Antonio Longo; Paolo Vigneri; Teresio Avitabile; Giovani Carlo Ettorre; Antonio Basile Journal: Insights Imaging Date: 2021-06-03
Authors: Michael C Y Tang; Myriam G Jaarsma-Coes; Teresa A Ferreira; Lorna Zwirs-Grech Fonk; Marina Marinkovic; Gregorius P M Luyten; Jan-Willem M Beenakker Journal: J Magn Reson Imaging Date: 2021-10-15 Impact factor: 5.119
Authors: Kirsten Koolstra; Jan-Willem Maria Beenakker; Peter Koken; Andrew Webb; Peter Börnert Journal: Magn Reson Med Date: 2018-11-13 Impact factor: 4.668
Authors: Teresa A Ferreira; Myriam G Jaarsma-Coes; Marina Marinkovic; Berit Verbist; Robert M Verdijk; Martine J Jager; Gregorius P M Luyten; Jan-Willem M Beenakker Journal: Neuroradiology Date: 2021-10-31 Impact factor: 2.804
Authors: Maria Failla; Rosario Caltabiano; Antonio Longo; Andrea Russo; Michele Reibaldi; Teresio Avitabile; Eliana Piombino; Cristina Colarossi; Lorenzo Colarossi; Elena Tirrò; Paolo Vigneri; Pietro Valerio Foti; Giuseppe Broggi Journal: Diagnostics (Basel) Date: 2022-03-05